The Pacific Pediatric Neuro-Oncology Consortium   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2017
NCT03231306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pacific Pediatric Neuro-Oncology Consortium

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Central Nervous System Neoplasms (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Medulloblastoma (Phase 1)

Neoplasms (Phase 2)

Nervous System Neoplasms (Phase 3)

Neurofibroma (Phase 2)

Neurofibroma, Plexiform (Phase 2)

Neurofibromatoses (Phase 2)

Neurofibromatosis 1 (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 12